دورية أكاديمية
أعرض في EDS

Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids.

التفاصيل البيبلوغرافية
العنوان: Co-Packaged PARP inhibitor and photosensitizer for targeted photo-chemotherapy of 3D ovarian cancer spheroids.
المؤلفون: Sorrin A; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Dasgupta A; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., McNaughton K; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Arnau Del Valle C; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Zhou K; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Liu C; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA., Roque DM; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, 21201, USA., Huang HC; Fischell Department of Bioengineering, University of Maryland, College Park, MD, 20742, USA. hchuang@umd.edu.; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, 21201, USA. hchuang@umd.edu.
المصدر: Cell & bioscience [Cell Biosci] 2024 Feb 06; Vol. 14 (1), pp. 20. Date of Electronic Publication: 2024 Feb 06.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 101561195 Publication Model: Electronic Cited Medium: Print ISSN: 2045-3701 (Print) Linking ISSN: 20453701 NLM ISO Abbreviation: Cell Biosci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, 2011-
مستخلص: Background: Within the last decade, poly(ADP-ribose) polymerase inhibitors (PARPi) have emerged in the clinic as an effective treatment for numerous malignancies. Preclinical data have demonstrated powerful combination effects of PARPi paired with photodynamic therapy (PDT), which involves light-activation of specialized dyes (photosensitizers) to stimulate cancer cell death through reactive oxygen species generation.
Results: In this report, the most potent clinical PARP inhibitor, talazoparib, is loaded into the core of a polymeric nanoparticle (NP-Tal), which is interfaced with antibody-photosensitizer conjugates (photoimmunoconjugates, PICs) to form PIC-NP-Tal. In parallel, a new 3D fluorescent coculture model is developed using the parental OVCAR-8-DsRed2 and the chemo-resistant subline, NCI/ADR-RES-EGFP. This model enables quantification of trends in the evolutionary dynamics of acquired chemoresistance in response to various treatment regimes. Results reveal that at a low dosage (0.01 μM), NP-Tal kills the parental cells while sparing the chemo-resistant subline, thereby driving chemoresistance. Next, PIC-NP-Tal and relevant controls are evaluated in the 3D coculture model at multiple irradiation doses to characterize effects on total spheroid ablation and relative changes in parental and subline cell population dynamics. Total spheroid ablation data shows potent combination effects when PIC and NP-Tal are co-administered, but decreased efficacy with the conjugated formulation (PIC-NP-Tal). Analysis of cell population dynamics reveals that PIC, BPD + NP-Tal, PIC + NP-Tal, and PIC-NP-Tal demonstrate selection pressures towards chemoresistance.
Conclusions: This study provides key insights into manufacturing parameters for PARPi-loaded nanoparticles, as well as the potential role of PDT-based combination therapies in the context of acquired drug resistance.
(© 2024. The Author(s).)
References: Nanomaterials (Basel). 2021 Jun 08;11(6):. (PMID: 34201069)
Cell Cycle. 2012 Oct 15;11(20):3837-50. (PMID: 22983061)
Oncotarget. 2017 Jun 6;8(23):38022-38043. (PMID: 28410237)
Cancer Lett. 2019 Aug 10;457:110-118. (PMID: 31071369)
Pharmaceutics. 2022 Aug 08;14(8):. (PMID: 36015275)
Sci Transl Med. 2016 Oct 26;8(362):362ps17. (PMID: 27797957)
Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621. (PMID: 28676700)
Cancer Res. 2018 Jan 15;78(2):558-571. (PMID: 29187403)
Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):E933-42. (PMID: 24572574)
ACS Pharmacol Transl Sci. 2021 Sep 15;4(5):1578-1587. (PMID: 36118950)
Proc Natl Acad Sci U S A. 2008 Nov 4;105(44):17079-84. (PMID: 18971340)
Small. 2018 Jul 1;:e1800236. (PMID: 29962083)
Sci Adv. 2023 Sep 8;9(36):eadi3441. (PMID: 37672582)
Photodiagnosis Photodyn Ther. 2022 Dec;40:103058. (PMID: 35944846)
Nat Rev Mol Cell Biol. 2006 Jul;7(7):517-28. (PMID: 16829982)
Front Chem. 2020 Nov 23;8:594619. (PMID: 33330383)
Int J Mol Sci. 2021 Sep 25;22(19):. (PMID: 34638660)
J Nanobiotechnology. 2020 Jan 2;18(1):1. (PMID: 31898555)
Br J Clin Pharmacol. 2022 Feb;88(2):742-752. (PMID: 34327724)
Br J Cancer. 2011 Oct 11;105(8):1114-22. (PMID: 21989215)
Front Cell Dev Biol. 2020 Sep 09;8:564601. (PMID: 33015058)
Int J Mol Sci. 2021 Apr 19;22(8):. (PMID: 33921561)
Drugs R D. 2020 Jun;20(2):55-73. (PMID: 32215876)
Oncoimmunology. 2020 Oct 27;9(1):1841393. (PMID: 33178498)
Transl Oncol. 2021 Nov;14(11):101198. (PMID: 34418731)
Biochem Biophys Res Commun. 2021 Feb 5;539:1-7. (PMID: 33388624)
Photochem Photobiol. 2020 Mar;96(2):232-259. (PMID: 31895481)
Int J Cancer. 2015 Apr 1;136(7):1485-93. (PMID: 24510760)
معلومات مُعتمدة: R01CA256710 United States GF NIH HHS; R01CA260340 United States GF NIH HHS
فهرسة مساهمة: Keywords: 3D spheroid; Cancer organoid; Ovarian cancer; PARP inhibitor; Photodynamic therapy; Photoimmunotherapy; Polymeric nanoparticles
تواريخ الأحداث: Date Created: 20240206 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC10845736
DOI: 10.1186/s13578-024-01197-6
PMID: 38321470
قاعدة البيانات: MEDLINE
الوصف
تدمد:2045-3701
DOI:10.1186/s13578-024-01197-6